Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

Journal of Neuroinflammation

Volumn 5, Issue , 2008, Pages

  Harkavyi, Alexander ^a   Abuirmeileh, Amjad ^a   Lever, Rebecca ^a   Kingsbury, Ann E ^b   Biggs, Christopher S ^c   Whitton, Peter S ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CYTOKINE; DOPAMINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIPOPOLYSACCHARIDE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; ANTIPARKINSON AGENT; ENDOTOXIN; ENDOTOXIN, ESCHERICHIA COLI; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; LEVODOPA; NERVE PROTEIN; PEPTIDE; VENOM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CIRCLING BEHAVIOR; CONTROLLED STUDY; DISEASE COURSE; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG EFFICACY; DRUG MECHANISM; EX VIVO STUDY; IN VIVO STUDY; MALE; NERVOUS SYSTEM DEVELOPMENT; NEUROCHEMISTRY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; LOCOMOTION; METABOLISM; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA; WISTAR RAT;

ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE; DRUG EVALUATION, PRECLINICAL; ENDOTOXINS; LEVODOPA; LOCOMOTION; MALE; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PEPTIDES; RATS; RATS, WISTAR; RECEPTORS, GLUCAGON; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VENOMS;

EID: 45549108268     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-5-19     Document Type: Article

References (28)

1. Clark D White FJ: Review: D1 dopamine receptor B the search for a function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1987, 1:347-388. 10.1002/syn.890010408 2971273
2. Vaux DL Korsmeyer SJ: Cell death in development. Cell 1999, 96:245-254. 10.1016/S0092-8674(00)80564-4 9988219
3. Gandhi S Wood NW: Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 2005, 14:2749-2755. 10.1093/hmg/ddi308
4. Block ML Zecca L Hong J-S: Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nature Neurosci 2007, 8(1):57-69. 10.1038/ nrn2038
5. Whitton PS: Inflammation as a potential causative factor in the aetiology of Parkinsons disease. Br J Pharmacol 2007, 150:963-976. 2013918 17339843 10.1038/sj.bjp.0707167
6. Hurtig HI: Problems with current pharmacological treatment of Parkinson's disease. Exp Neurol 1997, 144:10-16. 10.1006/exnr.1996.6380 9126144
7. Tatton NA Maclean-Fraser A Tatton WG Perl DP Olanow CW: A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 1998, 44:S142-148. 9749586
8. Ochu EE Rothwell NJ Waters CM: Caspases mediate 6-hydroxydopamine induced apoptosis but not necrosis in PC12 cells. J Neurochem 1998, 70:2637-2640. 9603231
9. Schapira AH: Causes of neuronal death in Parkinson's disease. Adv Neurol 2001, 86:155-162. 11553973
10. Perry T Lahiri DK Chen D Zhou J Shaw KTY Egan JM Grieg NH: A novel neurotrophic property of glucagons-like peptide 1: A promoter of nerve cell growth factor mediated differenciation in PC12 cells. J Pharmacol Exp Ther 2002, 300:958-966. 10.1124/jpet.300.3.958 11861804
11. Perry TA Haughey NJ Mattson MP Egan JM Grieg NH: Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002, 302:881-888. 10.1124/jpet.102.037481 12183643
12. Perry TA Holloway HW Weerasuriya A Mouton PR Duffy K Mattison JA Grieg NH: Evidence of GLp-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007, 203:293-301. 1850958 17125767 10.1016/j.expneurol.2006.09.028
13. Li L El-Kholy W Rhodes CJ Brubaker PL: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003, 278:471-478. 10.1074/jbc.M209423200 12409292
14. Bertilsson G Patrone C Zachrisson O Andersson A Dannnaeus K Heidrich J Kortesmaa J Mercer A Neilsen E Ronnholm H Wilkstrom L: Peptide hormone exndin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease. J Neurosci Res 2008, 86:326-38. 10.1002/jnr.21483 17803225
15. Zuch CL Nordstroem VK Briedrick LA Hoernig GR Granholm AC Bickford PC: Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol 2000, 427:440-454. 10.1002/1096-9861(20001120)427:3<440::AID-CNE10>3.0.CO;2-7 11054705
16. Yasuhara T Shingo T Date I: Intracerebral transplantation of genetically engineered cells for Parkinson's disease: Toward clinical application. Cell Transplant 2007, 16:125-132. 17474294
17. Gonzalez-Rey E Fernandez-Martin A Chomy A Delgado M: Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 2006, 55:824-32. 10.1136/gut.2005.084525 16401687
18. Abuirmeileh A Lever R Kingsbury AE Lees AJ Locke IC Knight RA Chowdrey HS Biggs CS Whitton PS: The corticotrophin releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson = s disease. Eur J Neurosci 2007, 26:417-423. 10.1111/ j.1460-9568.2007.05653.x 17650114
19. Abuirmeileh A Harkavyi A Lever R Biggs CS Whitton PS; Urocortin, a CRF-like peptide, restores key indicators of damage in a neuroinflammatory model of Parkinson's disease. J Neuroinflammation 2007, 4 :9. 1976313 17659087 10.1186/1742-2094-4-19
20. King AB Wolfe G Healy S: Clinical observations of exenatide treatment. Diabetes Care 2006, 29:1984. 10.2337/dc06-0864 16873820
21. Ungerstedt U: Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971,367:8993.
22. Biggs CS Fowler LJ Pearce BR Whitton PS: Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine and their metabolites in the rat brain: An in vivo microdialysis study. J Neurochem 1992, 59:1702-1708. 10.1111/ j.1471-4159.1992.tb11001.x 1402915
23. Naoi M Takahashi T Nagatsu T: Simple assay procedure for tyrosine hydroxylase activity by high-performance liquid chromatography employing coulometric detection with minimal sample preparation. J Chromatogr 1988, 427:229-38. 10.1016/0378-4347(88)80125-7 2900841
24. Abercrombie ED Bonatz AE Zigmond MJ: Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990, 525:36-44. 10.1016/0006-8993(90)91318-B 2123121
25. Cutillas B Espejo M Gil J Ferrer I Ambrosio S: Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration. Neuroreport 1999, 10:2605-2608. 10.1097/00001756-199908200-00030 10574377
26. Herrera AJ Castano A Venero JL Cano J Machado A: The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on the dopaminergic system. Neurobiol Dis 2000, 7:429-447. 10.1006/nbdi.2000.0289 10964613
27. Borta A Hoglinger GU: Dopamine and adult neurogenesis. J Neurochem 2007, 100:587-595. 10.1111/j.1471-4159.2006.04241.x 17101030
28. Meissner WT Hill MP Tison F Gross CE Bezard E: Neuroprotective strategies for Parkinson's disease: Conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 2004, 25:249-253. 10.1016/ j.tips.2004.03.003 15120490